Fig. 3

Drug candidates according to mutated cases. A Volcano plot to test drug sensitivity for single or double mutations (P ≤ 0.005 and log₂ FC ≤ 0.2). B Heatmap to summarize the three EGFR-TKIs’ sensitivity of EGFR-target (L858R and exon 19 deletion; n = 20) mutated PDCs classified by four molecular subtypes. P-values (rectangle size) were acquired by Wilcoxon rank-sum test, and fold changes (FCs; color-coded) were calculated to compare target mutation group with the wild-type. The number of mutation cases for each subtype is denoted on the y-axis. C Waterfall plot of the alpelisib response. RB1, TP53, and RB1/TP53 mutated PDCs are denoted. SCLC (S) and molecular subtype are labeled. The drug response comparison between mutation and wild-type investigated in both PDCs and cell lines, summarized in a table. D Heatmap of the alpelisib gene signature (n = 12) extracted from machine-learning and GSEA (pathway “MITOTIC G1 PHASE AND G1 S TRANSITION”, P < 0.1). PDCs were divided into drug-sensitive and -resistant groups, and the normalized AUC values are presented as a dot plot